Venus Remedies has announced the launch of its fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the brand name 'Tobracef' in domestic market for the first time.

The Drug Controller General of India had accorded its approval to Venus Remedies for launch of the fourth product developed by Venus Research Center, after completion of its multi-centered Phase III clinical trials and all related studies in March 2008.

Tobracef, a brand launched by the marketing division of the company, is reported to be a solution for the treatment of life-threatening infections caused by Pseudomonas aeruginosa/methicillin resistant Staphylococcus aureus in APE/cystic fibrosis patients.